Presentation is loading. Please wait.

Presentation is loading. Please wait.

Early treatment initiation: RV254/SEARCH 010 Study Group

Published byShanon Phelps Modified over 9 years ago

Similar presentations

Presentation on theme: "Early treatment initiation: RV254/SEARCH 010 Study Group"— Presentation transcript:

1 Early treatment initiation: RV254/SEARCH 010 Study Group
Jintanat Ananworanich on behalf of the RV254/SEARCH 010 Study Group

2 history of HIV exposure 17 days Fiebig I (RNA+, p24-, 3rd gen EIA-)
Characteristics (n=100) Values Median age 29 years MSM 92% Median duration from history of HIV exposure 17 days Fiebig I (RNA+, p24-, 3rd gen EIA-) Fiebig II (RNA+, p24+, 3rd gen EIA-) Fiebig III (3rd gen EIA+, WB-) 30% 15% 43% Median CD4 416 cells/mm3 Median HIV RNA 5.7 log CRF_01AE (n=62) 73% R5 tropism (n=39) 97%

3 Almost all Fiebig I patients had undetectable integrated HIV DNA in peripheral blood mononuclear cells during acute HIV 92% 53% Ananworanich J, et al CROI (abstract 47)

4 Almost all subjects treated during acute HIV had undetectable integrated HIV DNA after one year of antiretroviral treatment 100% 89%

5 Integrated HIV DNA at time of acute HIV infection
Not detected Not detected Not detected Fiebig I Fiebig III Ananworanich J, et al CROI (abstract 47)

6 Integrated HIV DNA at 24 weeks after ART
Not detected Not detected Fiebig I Fiebig III Chronic HIV

7 TDF + 3TC/FTC + EFV + RAL + MVC
MegaHAART vs. HAART Randomization (24 wks) TDF + 3TC/FTC + EFV + RAL + MVC vs. TDF + 3TC/FTC + EFV Followed by Total HIV DNA 2 LTR circles Integrated HIV DNA

8 Half of Fiebig I subjects have non-reactive
2nd generation EIA and/or Western Blot at 24 weeks after ART Non-reactive 2nd generation EIA Non-reactive/IND Western Blot CD4/CD8 ratio ≥ 1 Wk 0: 88% in Fiebig I vs. 20% in Fiebig III, p < 0.001 Wk 24: 64% in Fiebig I vs. 54% in Fiebig III, p = 0.6

9 Frequency of Gag-specific IFN-gamma response
and number of responders at baseline and 24 weeks after ART in the periphery 6/30 (20%) 2/17 (12%) CD4 CD8 Number of responders 4/30 (13%) 11/17 (65%)

10 Duration since history of HIV exposure, days
Using 4th Generation (Ag-Ab combo) Enzyme Immunoassay to distinguish two groups of Fiebig I subjects Fiebig I subjects RNA+/p24-/3rd gen- (n=25) 4thG stage 1 4th gen- (n=18) 4thG stage 2 4th gen+ (n=7) P value HIV RNA, log10copies/ml 4.6 5.7 0.005 HIV DNA, copies/106 PBMC 7 312 0.002 Duration since history of HIV exposure, days 12.5 17 0.06 Ananworanich J, et al. Retrovirology 2013

11 Where we are now in RV254/ SEARCH 010 Goal
Hypothesis 1 Is early ART alone sufficient to cure in patients treated during Fiebig I? Hypothesis 2 Will therapeutic HIV vaccine + early ART result in better viremic control vs. early ART alone? Where we are now in RV254/ SEARCH 010 ART initiated during acute HIV restricted infection in PBMCs and TCM A series of randomized trials are being developed Goal Functional cure (Viremic control without ART) Hypothesis 3 Will HDACi + early ART result in depletion of reservoir/cure vs. early ART alone? Hypothesis 4 Will anti-inflammatory drugs + early ART result in less immune activation and reservoir vs. early ART alone?

12 RV254/SEARCH 010 Acknowledgement
Thai Red Cross/Chula AFRIMS Volunteers Funding from US Military HIV Research Program MHRP Alexandra Schuetz Rapee Trichavaroj Vatcharain Assawadarachai Yuwadee Phuangngern Siriwat Akapirat Nantana Tantibul Panadda Sawangsinth Susan Mason Bessara Nuntapinit Wanwarang Khobchit Sakuna Suksawad Ajchariyarat Sangdara Kultida Poltavee Hathairat Savadsuk Suwittra Chaemchuen Surat Jongrakthaitae Chayada Sajiaweerawan Nipattra Tragonlugsana    Putida  Saetun Nelson Michael Jerome Kim Merlin Robb Hendrik Streeck Diane Bolton Bonnie Slike Sodsai Tovanabutra Gustavo Kijak Jean-Louis Excler Praphan Phanuphak Kiat Ruxrungtham Mark de Souza Frits van Griensven Thep Chalermchai James LK Fletcher Eugene Kroon Nipat Teeratakulpisarn Rungsun Rerknimitr Wiriyaporn Ridtitid Sukalya Lerdlum Supranee Buranapraditkun Duanghathai Suttichom Somprartthana Rattanamanee Peeraya Mangu Sasiwimol Ubolyam Mantana pothisri Phandee Wattanaboonyongcharoen Ponlapat Rojnuckarin Sopark Manasnayakorn Suteeraporn Pinyakorn NIAID Irini Sereti Daniel Douek Netanya Sandler Mary Marovich NCI Jacob Estes Robin Dewar Adam Rupert SAIC-Frederick UCSF Yale Frank Maldarelli Mary Kearney Ann Wiggins Industry Victor Valcour Thai GPO (TDF, 3TC, EFV, LPV/r) Gilead (TDF, FTC) Merck (EEV, RAL) Pfizer (MVC) Monogram (Trofile) VGTI Serena Spudich Idil Kore UMN Nicolas Chomont Claire Vandergeeten Rafick Sekaly Elias Haddad Lydie Trautmann Huntington Memorial Timothy Schacker Napaporn Sailasuta

Download ppt "Early treatment initiation: RV254/SEARCH 010 Study Group"

Similar presentations

Emerging patterns of drug resistance and viral tropism in cART-naïve and failing patients infected with HIV-1 subtype C Thumbi Ndung’u, BVM, PhD Associate.

Emerging patterns of drug resistance and viral tropism in cART-naïve and failing patients infected with HIV-1 subtype C Thumbi Ndung’u, BVM, PhD Associate.
New concepts in HIV: HIV immunopathogenesis, treatment and vaccine strategies - report back from pre-conference Nicolas Chomont VGTI-Florida.

New concepts in HIV: HIV immunopathogenesis, treatment and vaccine strategies - report back from pre-conference Nicolas Chomont VGTI-Florida.
Purging the HIV-1 Reservoir Through the Disruption of the PD-1 Pathway

Purging the HIV-1 Reservoir Through the Disruption of the PD-1 Pathway
VIREAD (Tenofovir DF) Update. Viread Update  Pharmacokinetics  Safety & Tolerability  Efficacy  Virology.

VIREAD (Tenofovir DF) Update. Viread Update  Pharmacokinetics  Safety & Tolerability  Efficacy  Virology.
Hiromi Imamichi, Robin L. Dewar, Da Wei Huang, Dun Liang, Catherine R. Rehm, Ellen Paxinos, Michael Brown, Yan Guo, Colleen Ludka, Colleen Hadigan, Richard.

Hiromi Imamichi, Robin L. Dewar, Da Wei Huang, Dun Liang, Catherine R. Rehm, Ellen Paxinos, Michael Brown, Yan Guo, Colleen Ludka, Colleen Hadigan, Richard.
Short video on patients’ perspectives on cure

Short video on patients’ perspectives on cure
Interactive Workshop “HIV Cure 101”: Challenges in identifying and targeting the HIV reservoir Sarah Palmer Centre for Virus Research Westmead Millennium.

Interactive Workshop “HIV Cure 101”: Challenges in identifying and targeting the HIV reservoir Sarah Palmer Centre for Virus Research Westmead Millennium.
Controversies in HIV Cure Research 18.3 0 Debate 1. Is there ongoing replication under HAART? Mario Stevenson and Frank Maldarelli Moderator: Steve Deeks.

Controversies in HIV Cure Research Debate 1. Is there ongoing replication under HAART? Mario Stevenson and Frank Maldarelli Moderator: Steve Deeks.
CXCR4-tropism and the preferential establishment of an HIV-reservoir in naïve CD4+ T-cells among HIV-infected Ugandan children Theodore Ruel 1, Jane Achan.

CXCR4-tropism and the preferential establishment of an HIV-reservoir in naïve CD4+ T-cells among HIV-infected Ugandan children Theodore Ruel 1, Jane Achan.
EARLY ANTIRETROVIRAL TREATMENT HIV Cure Research Training Curriculum (CUREiculum) Early Antiretroviral (ART) Treatment Module by: Scientific Leads: Dr.

EARLY ANTIRETROVIRAL TREATMENT HIV Cure Research Training Curriculum (CUREiculum) Early Antiretroviral (ART) Treatment Module by: Scientific Leads: Dr.
2014 “Towards an HIV Cure” symposium Melbourne A novel assay that precisely measures the size of the latent HIV reservoir reveals that ART-nai ̈ ve individuals.

2014 “Towards an HIV Cure” symposium Melbourne A novel assay that precisely measures the size of the latent HIV reservoir reveals that ART-nai ̈ ve individuals.
2014 “Towards an HIV Cure” symposium Melbourne The Immune Checkpoints PD-1, LAG-3 and TIGIT are Biomarkers of HIV Infected Cells During ART and Identify.

2014 “Towards an HIV Cure” symposium Melbourne The Immune Checkpoints PD-1, LAG-3 and TIGIT are Biomarkers of HIV Infected Cells During ART and Identify.
Roles of Protease Inhibitors for HIV-infected Children Jintanat Ananworanich.

Roles of Protease Inhibitors for HIV-infected Children Jintanat Ananworanich.
Cell- and Tissue-based Measures of Viral Persistence Are Associated with Immune Activation and PD-1-Expressing CD4+ T cells H Hatano 1, V Jain 1, PW Hunt.

Cell- and Tissue-based Measures of Viral Persistence Are Associated with Immune Activation and PD-1-Expressing CD4+ T cells H Hatano 1, V Jain 1, PW Hunt.
Detection of HIV-1 RNA in seminal plasma samples from treated patients with undetectable HIV-1 RNA in blood plasma Marcelin AG 1, Tubiana R 1, Lambert-Niclot.

Detection of HIV-1 RNA in seminal plasma samples from treated patients with undetectable HIV-1 RNA in blood plasma Marcelin AG 1, Tubiana R 1, Lambert-Niclot.
HIV-1 DNA levels after antiretroviral therapy in primary infection predict disease progression: the SPARTAC Trial James Williams 1,2,3, Jacob Hurst 1,2,3,

HIV-1 DNA levels after antiretroviral therapy in primary infection predict disease progression: the SPARTAC Trial James Williams 1,2,3, Jacob Hurst 1,2,3,
T-cell activation positively correlates with cell-associated HIV-DNA level in PBMCs in viremic patients with acute or chronic HIV-1 infection Laurence.

T-cell activation positively correlates with cell-associated HIV-DNA level in PBMCs in viremic patients with acute or chronic HIV-1 infection Laurence.
J.L.K. Fletcher, S. Pinyakorn, M. de Souza, S. Akapirat, R. Trichavaroj, T. Pankam, E. Kroon, D. Colby, P. Prueksakaew, D. Suttichom, J.H. Kim, P. Phanuphak,

J.L.K. Fletcher, S. Pinyakorn, M. de Souza, S. Akapirat, R. Trichavaroj, T. Pankam, E. Kroon, D. Colby, P. Prueksakaew, D. Suttichom, J.H. Kim, P. Phanuphak,
Acute HIV infection detection and control reduces HIV infectiousness and transmission risk behavior among men who have sex with men in Bangkok, Thailand.

Acute HIV infection detection and control reduces HIV infectiousness and transmission risk behavior among men who have sex with men in Bangkok, Thailand.
Concepts in Basic Science and Translational Research

Concepts in Basic Science and Translational Research

Similar presentations

Ads by Google